https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-14 / Ther Apher Dial 2021 Aug;25(4):415-424
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-14 / Ther Apher Dial 2021 Aug;25(4):415-4242021-05-14 00:00:002023-01-31 12:56:12Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-03-01 / Gan To Kagaku Ryoho 2021 Mar;48(3):388-390
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-03-01 / Gan To Kagaku Ryoho 2021 Mar;48(3):388-3902021-03-01 00:00:002021-03-01 00:00:00Neoadjuvant Hyperthermia and Chemoradiotherapy for Borderline Resectable Pancreatic Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-10-01 / Anticancer Res 2020 Oct;40(10):5765-5776
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-10-01 / Anticancer Res 2020 Oct;40(10):5765-57762020-10-01 00:00:002020-10-01 00:00:00Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-19 / Int J Mol Sci 2020 Jul;21(14)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-19 / Int J Mol Sci 2020 Jul;21(14)2020-07-19 00:00:002020-07-19 00:00:00Modulated Electro-Hyperthermia Resolves Radioresistance of Panc1 Pancreas Adenocarcinoma and Promotes DNA Damage and Apoptosis In Vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-02 / Signal Transduct Target Ther 2020 Jul;5(1):114
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-02 / Signal Transduct Target Ther 2020 Jul;5(1):1142020-07-02 00:00:002020-07-02 00:00:00Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / J Immunother Cancer 2020 07;8(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / J Immunother Cancer 2020 07;8(2)2020-07-01 00:00:002021-05-12 07:32:39Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-16 / Cancer Cell 2020 03;37(3):289-307.e9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-16 / Cancer Cell 2020 03;37(3):289-307.e92020-03-16 00:00:002020-08-26 12:23:32Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-01 / Cytotherapy 2020 01;22(1):6-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-01 / Cytotherapy 2020 01;22(1):6-152020-01-01 00:00:002020-08-26 13:55:22Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-01 / Am J Cancer Res 2019;9(11):2456-2468
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-01 / Am J Cancer Res 2019;9(11):2456-24682019-11-01 00:00:002019-11-01 00:00:00Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-17 / Pathol. Res. Pract. 2019 Dec;215(12):152691
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-17 / Pathol. Res. Pract. 2019 Dec;215(12):1526912019-10-17 00:00:002019-10-17 00:00:00Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
